Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin

Lennham Pharmaceuticals has announced that the United States Patent & Trademark Office issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of psilocybin or psilocin.

Category Press Release
Published in Businesswire